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1. Introduction 
Parkinson’s disease (PD) is a relatively common neurological disorder in the elderly. However, 
only 76% of patients considered clinically to have PD are confirmed to have PD after 
postmortem examination (Hughes et al., 1993). The most common atypical form of 
parkinsonism is multiple system atrophy (MSA) (Hughes et al., 1994). MSA is clinically 
characterized by a combination of parkinsonian, autonomic, pyramidal and/or cerebellar 
symptoms and signs. The differential diagnosis of disorders with parkinsonism is very 
important because prognosis and treatment options differ substantially (Wenning et al., 1997). 
However, although the diagnoses of PD and MSA are based on current clinical criteria (Gelb et 
al., 1999; Gilman et al., 1999), they continue to lack sufficient specificity (Hughes et al., 1992; 
Litvan et al., 1997), particularly early in the disease course (Osaki et al., 2002).  
Extrapyramidal signs in dementia with Lewy bodies (DLB) resemble those seen in PD, 
although less rest tremor and left/right asymmetry, but more severe rigidity, favors a 
diagnosis of DLB. The subtle differences in the nature of extrapyramidal signs between DLB 
and PD may be of limited help in clinically differentiating the two disorders. This is 
particularly true in the early disease stages because the sensitivity of the clinical diagnosis of 
DLB based on the consensus criteria of the DLB International Workshop was 0.22 compared 
with 0.83 based on a neuropathological diagnosis (McKeith et al., 1996).  
The clinical features of PD and autosomal recessive juvenile parkinsonism (AR-JP) are also 
similar. Thus, it may be difficult to differentiate these two disorders. Neuropathological 
studies in AR-JP have revealed selective degeneration with gliosis of the pigmented neurons 
of the substantia nigra and locus ceruleus, but generally no Lewy bodies (Takahashi et al., 
1994; Mori et al., 1998; Paviour et al., 2004), suggesting that the pathological findings and 
disease process of AR-JP differ from those of PD.  
Metaiodobenzylguanidine (MIBG) is a physiological analogue of noradrenaline 
(norepinephrine) (Wieland et al., 1981) and 123I-MIBG myocardial scintigraphy has been 
used to evaluate postganglionic cardiac sympathetic innervation in parkinsonian disorders 
(Braune et al., 1999; Orimo et al., 1999; Druschky et al., 2000; Taki et al., 2000; Suzuki et al., 
2005). 123I-MIBG myocardial scintigraphy can be performed safely and is clinically used to 
estimate local myocardial sympathetic nerve damage in PD (Braune et al., 1998; Orimo et al., 
1999; Takatsu et al., 2000a). Myocardial innervation imaging using 123I-MIBG has also 
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emerged as a useful method to confirm or exclude the presence of PD (Jost et al., 2010). 
Thus, 123I-MIBG scintigraphy is the only method that can distinguish with a high degree of 
sensitivity and specificity between parkinsonian disorders and PD.  
In the present study, we evaluated 123I-MIBG myocardial scintigraphy in patients with PD, 
DLB, AR-JP, and MSA in order to enhance the differentiation of PD from these other 
neurological diseases that mimic PD. 
2. Material and methods 
2.1 Patients 
A total of 74 subjects were enrolled prospectively based on the criteria outlined below for PD 
(n = 36), DLB (n = 6), MSA (n = 14), AR-JP (n = 2), and normal control groups (NC; n = 16). 
There was no significant difference in age between patients with parkinsonism and NC (P = 
0.25), and none of the enrolled subjects had clinical evidence of diabetes mellitus or 
cardiovascular disease. Cases were excluded if no relevant clinical information was provided. 
In addition, none of the participating subjects were taking drugs that might interfere with 123I-
MIBG uptake (Solanki et al., 1992; Wafelman et al., 1994; Braune et al., 2001).   
The diagnosis of probable DLB was made based on the criteria of DLB adopted by the 
International National Workshop on DLB (McKeith et al., 1996). Six patients with DLB had 
early recurrent visual hallucinations and delusions unrelated to therapy, marked fluctuations 
in alertness, progressive cognitive decline, and spontaneous motor features of parkinsonism. 
These psychiatric symptoms became worse with administration of anticholinergic agents and 
dopamine agonists. 
Thirty-six patients with idiopathic PD (Hoehn and Yahr (HY) stage 1, 8 patients; HY 2, 22 
patients; HY 3, 6 patients) showed two or more of the following cardinal features of PD: rest 
tremor, bradykinesia, muscular rigidity, loss of postural reflexes, and unilateral symptoms; 
thus fulfilling standard diagnostic criteria 6. All PD patients had a good or excellent initial 
response to levodopa treatment.   
Fourteen patients presented with probable MSA according to the criteria reported by 
Gilman and colleagues (Gilman et al., 1999); all showed extrapyramidal symptoms and 
corticospinal dysfunction, sporadic adult-onset, and rapid disease progression without 
dementia. These patients tended to be unresponsive to levodopa or dopamine agonist 
therapy.   
The study included two patients with AR-JP. Both had consanguineous parents and were 
only first generation. Their clinical features included early-onset (in the 20s) and levodopa-
responsive parkinsonism, diurnal fluctuation, and slow progression of the disease. The 
disease presented initially with dystonic posture of the legs followed by a gradual 
development of parkinsonism. Their parkinsonian symptoms were responsive to levodopa, 
although a gradual decline in the efficacy was noted. The parkinsonian triad was mild, and 
the tremor was usually fine and postural. The levodopa efficacy was sufficient and the 
clinical course was benign; however, both showed a clear wearing-off phenomenon.   
2.2 
123
I-MIBG myocardial scintigraphy 
123I-MIBG myocardial scintigraphy was performed in all subjects using an intravenous 
injection of 111 MBq 123I-MIBG (Daiichi Radioisotope Laboratories Co, Tokyo, Japan). Single 
positron emission computed tomographic and planar images of the chest were obtained 
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gamma camera (MULTI SPECT III, Siemens, IL, USA) equipped with low-energy and high-
resolution collimators. The photopeak of 123I was centered at 159 keV with a 20% energy 
window. For the anterior planar image, the data was acquired for 4 minutes with a 256 x 256 
matrix for image acquisition. The organ uptake of 123I-MIBG was determined by setting the 
region of interest (ROI) on the anterior view. An ROI was drawn in the left ventricle of the 
heart and an angular ROI was also set in the upper mediastinum in early imaging, with the 
same also used for the delayed imaging. The heart to mediastinum ratio (H/M ratio) 
represented the average counts per pixel in the heart (H) and mediastinum (M).   
2.3 Statistical analysis 
All data are expressed as mean ± standard deviations. Differences in continuous variables 
were examined for statistical significance using Student’s t-test. A P value less than 0.01 was 
considered to denote a significant difference. All tests were performed with the STATA 8.0 
software program (STATA Corporation, College Station, TX). The AR-JP group was 
excluded from the analysis because of the small number of subjects.     
3. Results 
The normal mean values of the H/M ratio in 16 NC were 2.04 (SD 0.18) (range; 1.86-2.55) in 
the early phase and 2.12 (0.15) (1.91-2.43) in the delayed phase (Table 1). The mean H/M 
ratio in the early/delayed phase was 1.25 (0.11) (1.11-1.37)/1.18 (0.12) (1.01-1.39) in patients 
with DLB, 1.45 (0.19) (1.13-1.79)/1.36 (0.22) (1.03-1.99) in those with PD, and 1.88 (0.27) (1.46-
2.34)/1.88 (0.40) (1.33-2.47) in those with MSA, respectively. In patients with DLB, the H/M 
ratio in the early/delayed phases was significantly lower than in MSA and NC groups. In 
patients with PD, the H/M ratio in the early/delayed phases was also significantly lower 
than that in MSA and NC groups. In the early phase, the mean value of H/M ratio in 
patients with DLB was significantly lower than that in patients with PD. However, the H/M 
ratio in the delayed phase for patients with DLB was lower than that in PD patients, 
although the difference was not significant (P = 0.015) (Table 1). Overall, there was no 
significant difference in the early/delayed H/M ratio between the MSA and NC groups (P = 
0.077, P = 0.054, respectively). In the two patients with AR-JP, the H/M ratios in the 
early/delayed phases were preserved within the same range (1.99/2.13, 2.00/2.10, 
respectively) as the mean value of H/M ratio in NC (Figure 1).  
 





Early image Delayed image 
DLB 6 (5/1) 68 ± 8 1.3 ± 0.1*†¶ 1.2 ± 0.1*† 39 ± 5 
PD 36 (24/12) 64 ± 9 1.5 ± 0.2*† 1.4 ± 0.2*† 42 ± 6 
MSA 14 (8/6) 63 ± 8 1.9 ± 0.3 ns 1.9 ± 0.4 ns 35 ± 7 ns 
NC 16 (11/5) 64 ± 9 2.0 ± 0.2 2.1 ± 0.2 35 ± 4 
Data are mean±SD. *P < 0.001, compared with normal control subjects; ns, not significant, compared 
with normal control subjects; †P < 0.001, compared with MSA; ¶P < 0.004, compared with PD. DLB, 
dementia with Lewy bodies; PD, Parkinson’s disease; MSA, multiple system atrophy; NC, normal 
control subjects; M, male; F, female; H/M ratio, heart to mediastinum ratio. 
Table 1. Subjects’ background and data summary  
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Fig. 1. Short-axis views of 123I-MIBG myocardial scintigraphy 
Short-axis views in the early phase of single-photon emission computed tomography of 
iodine-123–labeled metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy in a 62-
year-old man with autosomal recessive juvenile parkinsonism (a), a 58-year-old man with 
idiopathic Parkinson’s disease (Hoehn and Yahr Stage II, b), and a healthy 62-year-old man (c). 
4. Discussion 
The major findings of the present study were that 1) 123I-MIBG uptake of the myocardium 
was significantly lower in patients with Lewy body disease (LBD) including PD and DLB 
than in controls, 2) the mean values of both the early and delayed H/M ratios in patients 
with DLB were significantly lower than those in patients with PD, and 3) the mean values of 
H/M ratios in the early and delayed phases in patients with MSA and AR-JP were well 
within the range of healthy control subjects.  
Decreased cardiac uptake of 123I-IMIBG has been reported in LBD (Yoshita et al., 2001; 
Watanabe et al., 2001; Nagayama et al., 2005; Suzuki et al., 2006; Suzuki et al., 2007), and a 
role for postganglionic cardiac sympathetic nerves in PD was demonstrated (Orimo et al., 
2001). Thus, reduced uptake of 123I-MIBG is considered to reflect lesions in postganglionic 
cardiac sympathetic neurons in PD. Lower amounts of cardiac 123I-MIBG uptake were also 
reported in DLB, even in the early disease stage (Watanabe et al., 2001; Yoshita et al., 2001; 
Suzuki et al., 2006). These studies suggested that uptake of 123I-MIBG reflects myocardial 
sympathetic nerve function and that lowered myocardial 123I-MIBG uptake could reflect a 
disturbance of the postganglionic cardiac sympathetic nerves. In this context, the present 
study indicated marked reduction of 123I-MIBG uptake in DLB, indicating impairment of the 
cardiac sympathetic nervous system in this disorder and possible lesions in the 
postganglionic cardiac sympathetic neurons in DLB, as in PD (Suzuki et al., 2006). These 
observations might indeed reflect actual cardiac sympathetic denervation, which precedes 
the neuronal loss in the sympathetic ganglia (Orimo et al., 2005). Cardiac uptake of 6-18F 
fluorodopamine on positron emission tomography, which can also assess cardiac 
sympathetic innervation, was decreased in patients with PD (Goldstein et al., 1997; 
Goldstein et al., 2000), supporting that cardiac sympathetic denervation occurs in LBD.  
Decreased cardiac uptake of MIBG has been reported even in the early stages of PD, which 
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Orimo et al. (2007) immunohistochemically examined heart tissues, the sympathetic ganglia, 
and the medulla oblongata at the level of the dorsal vagal nucleus in 20 patients with 
incidental Lewy body disease (ILBD), which is thought to represent a presymptomatic stage 
of PD, and 10 control subjects, using antibodies against TH and NF. TH- and NF-
immunoreactive nerve fibers of fascicles in the epicardium were well preserved in 10 of the 
20 patients with ILBD and in all control subjects. In contrast, TH-immunoreactive nerve 
fibers had almost entirely disappeared in 6 patients and were moderately decreased in 4 of 
the 20 patients with ILBD. In addition, none of these ILBD patients showed neuronal loss in 
the dorsal vagal nucleus or sympathetic ganglia (Orimo et al., 2007). These findings 
suggested that degeneration of the cardiac sympathetic nerve begins even in the 
presymptomatic stage of PD, when neuronal loss in the dorsal vagal nucleus is not yet 
evident. 
The present study also revealed relatively preserved cardiac 123I-MIBG uptake in MSA, 
consistent with previous studies (Yoshita et al., 1998; Nagayama et al., 2005). Taki et al. 
(2004) previously reported preserved 123I-MIBG uptake in MSA, suggesting that central and 
preganglionic neurons are predominantly affected, while postganglionic sympathetic 
neurons are usually spared. Thus, cardiac 123I-MIBG uptake could be unimpaired, indicating 
the significance of 123I-MIBG imaging as a discriminator between PD and MSA (Yoshita et 
al., 1998; Braune et al., 1999; Orimo et al., 1999; Druschky et al., 2000; Takatsu et al.; 2000a, 
2000b). Postmortem studies demonstrated that postganglionic cardiac sympathetic nerve 
fibers are markedly decreased in all PD patients, but not necessarily in those with MSA, 
providing substantial evidence of discrepant 123I-MIBG uptake between PD and MSA 
(Orimo et al., 2001, 2002). Recent myocardial innervation imaging with 123I-MIBG 
scintigraphy also demonstrated a high sensitivity for PD detection and adequate specificity 
for discriminating between PD and MSA (Köllensperger et al., 2007; Chung et al., 2009; 
Fröhlich et al., 2010). However, Nagayama et al. (2010) recently suggested that MSA cannot 
consistently be distinguished from PD based on 123I-MIBG myocardial scintigraphy. Their 
study clearly showed that cardiac MIBG uptake is not always preserved in patients with 
MSA and that approximately 30% of patients with MSA showed decreased MIBG uptake 
without any correlation to disease duration or severity. The precise mechanisms underlying 
low cardiac MIBG uptake in MSA patients remain unclear. The same authors also reported 
an autopsied patient with MSA showing low cardiac MIBG uptake with an incidental LB 
pathology in addition to a typical MSA pathology (Nagayama et al, 2008). Therefore, the 
presence of LB pathology may be a suitable explanation for the low myocardial MIBG 
uptake observed in patients with MSA. The second consensus statement on the diagnosis of 
MSA gave no advice about the usefulness and reliability of MIBG scintigraphy scanning in 
the workup of suspected patients with MSA (Gilman et al., 2008), while the Quality 
Standards Subcommittee of the American Academy of Neurology found insufficient 
evidence to recommend MIBG cardiac imaging for differentiating PD from MSA 
(Suchowersky et al., 2006).  
In contrast, myocardial uptake of 123I-MIBG in AR-JP was normal in our study (Suzuki et al., 
2005). The H/M ratios in the early and delayed phases in two patients were well within the 
range for healthy control subjects. These findings might explain the tendency for cardiac 
sympathetic function to be normal in patients with AR-JP. The pathological background of 
PD is a systemic distribution of Lewy bodies and Lewy neuritis, spreading to the peripheral 
autonomic nervous system, including the cardiac plexus (Wakabayashi et al., 1997; Iwanaga 
et al., 1999). Thus, although the present study included only two patients with AR-JP, it 
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indicated that cardiac sympathetic nerve denervation occurs in PD, and thus accounted for 
the decrease in cardiac uptake of 123I-MIBG in PD patients and not in those with AR-JP. In 
this regard, quantification of cardiac 123I-MIBG uptake is considered a valuable tool to 
identify patients with PD and to distinguish them from patients with other parkinsonian 
syndromes, including AR-JP (Braune et al., 1999; Orimo et al., 1999; Druschky et al., 2000; 
Taki et al., 2000). However, a recent study of PD patients showed a low myocardial 123I-
MIBG uptake in one patient with PARK2 mutation and autonomic dysfunction, while early-
phase MIBG uptake was normal in all other patients free of autonomic dysfunction 
(Yoritaka et al., 2011). Similar to the above study, a low uptake of 123I-MIBG was reported in 
1 of 4 patients with PARK2 mutations, with disease duration of 12 years and ill-defined 
autonomic dysfunction (Quattrone et al., 2008). In addition, 3 patients in the above study 
who had low 123I-MIBG uptake were slightly older than the other patients. Incidentally, 
Estorch et al. (1995) reported that the uptake of 123I-MIBG decreases with age, suggesting 
that aging could affect patients with PARK2 mutations. Decreased myocardial uptake of 123I-
MIBG is also considered to indicate the presence of -synuclein aggregates in the axons of 
PD patients (Orimo et al., 2008), while the H/M ratio of patients with PARK2 mutations was 
reported to be within the range of the normal controls (Suzuki et al., 2005). Moreover, 
postmortem examination of patients with PARK2 mutations showed well preserved 
tyrosine hydroxylase immunoreactive nerve fibers in the epicardium (Orimo et al., 2005), 
suggesting normal functioning myocardial sympathetic nerve terminals in patients with 
PARK2 mutations. MIBG scintigraphy might be a marker for -synuclein in patients with 
PARK2 mutations; however, there are no pathological reports on the presence of Lewy 
bodies in patients with PARK2 mutations with low MIBG uptake (Yoritaka et al., 2011). 
5. Conclusion 
The results of the present study indicated that inclusion of 123I-MIBG myocardial 
scintigraphy in the clinical assessment can potentially increase the chance of correctly 
distinguishing LBD from the other parkinsonian syndromes. Our study also indicated a 
difficulty in the differential diagnosis of PD from DLB by 123I-MIBG findings alone. In 
comparison with PD, mild degeneration of the cardiac sympathetic nervous system may 
occur in patients with MSA. Finally, abnormalities of 123I-MIBG uptake in genetically 
identified cases of AR-JP are rare and inconsistent findings. Together, our findings support 
the conclusions of previous studies that 123I-MIBG myocardial scintigraphy is a potentially 
useful tool for the differential diagnosis of LBD based on the decreased 123I-MIBG uptake in 
cardiac postganglionic sympathetic nerve fibers. 
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